asasantin retard 200 mg / 25 mg
boehringer ingelheim international gmbh - dipyridamol / acetylsalisylsyre - kapsel med modifisert frisetting, hard - 200 mg / 25 mg
creon 10000
viatris as - lipase / amylase / protease - enterokapsel, hard - 10000 ie / 8000 ie / 600 ie
creon 25000
viatris as - lipase / amylase / protease - enterokapsel, hard - 25000 ie / 18000 ie / 1000 ie
creon 40000
mylan - asker - lipase / amylase / protease - enterokapsel, hard - 40000 e / 25000 e / 1600 e
aponova 200 mg
alternova - dipyridamol - depotkapsel, hard - 200 mg
nurofen 100 mg
reckitt benckiser healthcare (nordics) a/s - ibuprofen - tyggekapsel, myk - 100 mg
persantin retard 200 mg
boehringer ingelheim international gmbh - dipyridamol - kapsel med modifisert frisetting, hard - 200 mg
toilax 5 mg
orion corporation orion pharma - bisakodyl - enterotablett - 5 mg
toilax kombinasjonspakning 10 mg/ dose / 5 mg
orion corporation orion pharma, espoo - bisakodyl - enterotablett, rektalvæske, suspensjon - 10 mg/ dose / 5 mg
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.